Atopic Dermatitis Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Competitive Landscape & Forecast, 2020 - 2026
Report ID: GMI2744
Atopic Dermatitis Therapeutic Market size is projected to experience significant growth from 2018 to 2024.
Atopic dermatitis therapeutic market is expected to witness significant growth due to rising cases of Atopic dermatitis with the increase in prevalence of food allergies exacerbating Atopic Dermatitis. Escalation in consumption of chicken eggs, cow’s milk, peanuts, wheat, nuts, soy and fish increase the chances of developing food allergies that result in development of atopic dermatitis. Globally, around one-third of the children with atopic dermatitis are diagnosed with food allergy.
Introduction of the emerging therapies such as baricitinib (Eli Lilly and Company), Tralokinumab (LEO Pharma), Furestem (Kangstem Biotech), and other therapies is expected to fuel market growth in upcoming years. Robust pipeline, advancement in treatment, growing government and pharmaceutical companies’ initiatives for the development of the novel therapies for atopic dermatitis will result in business expansion. Immense need to develop novel therapies for severe recalcitrant patients that do not respond to the existing therapies is the major reason behind extensive molecule in development pipeline.
Factors such as lack of awareness regarding the treatment and diagnosis, patent expiry of marketed drugs, challenges in performing clinical trials, genericization of the existing drugs and poor patient adherence of marketed drugs are hindering the market growth.
Increasing use of conventional systemic immunosuppressants such as azathioprine and cyclosporine that are largely used for the treating moderate to severe patients will boost the product demand. Therefore, systemic immunosuppressants business is expected to witness the significant growth during forecasted period. Approval of novel therapies such as Phosphodiesterase-4 (PDE-4) Inhibitors i.e. Eucrisa (crisaborole) in 2016 and Interleukin Inhibitor-4/ Interleukin Inhibitor-13 (IL-4/IL-13) in 2017 has changed the treatment landscape of atopic dermatitis.
The market for topical route of administration products holds larger market share compared to the oral and injectable products owning to the advantages of topical products such as high patience adherence, cost effectiveness.
U.S. atopic dermatitis market is the largest market in North America as well as in the world’ owing to high prevalence of food and skin allergies, and high prevalence of atopic dermatitis. Also, other factors such as adoption of novel medications, better reimbursement policies and launch of the maximum number of drugs U.S. augment market expansion.
Asia Pacific atopic dermatitis market should grow with an explosive rate due to increasing healthcare expenditure, improving healthcare infrastructure and awareness. Moreover, growing need to address lifestyle induced disorders will play a productive role in introducing atopic dermatitis therapies during the forecast period.
Some of the key industry players include Regeneron Pharmaceuticals Inc, Eli Lilly and Company, LEO Pharma A/S, Glaxosmithkline plc, Novartis AG, Kang Stem Biotech Co., Ltd, Sanofi S.A and others. Among these players, Eli Lilly and Company, LEO Pharma, Kang Stem Biotech Co., Ltd., Glaxosmithkline plc and others are focusing on developing novel therapies for the treatment of Atopic Dermatitis. In January 2018, Regeneron Pharmaceuticals, Inc and Sanofi had accelerated and expanded the investment for the clinical development of the Dupilumab for atopic dermatitis.
Atopic Dermatitis Market by product, 2013-2024 (USD Million)
- Anti-inflammatory agents
- Calcineurin Inhibitors
- Interleukin Inhibitors
- Phosphodiesterase-4 (PDE-4) Inhibitors
Atopic Dermatitis Market by Route of Administration, 2013-2024 (USD Million)
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Novartis AG
- Connetics Corporation
- Regeneron Pharmaceuticals Inc.
- Fujisawa Healthcare
- Eli Lilly and Company
- LEO Pharma A/S
- Kang Stem Biotech Co., Ltd.
- Glaxosmithkline plc
- Sanofi S.A
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Take a free trial of GMIPuse, our report store; designed to provide clients a range of market research services, all on a single platform.Start Your Free Trial
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.